Drugstore.com
This article was originally published in The Tan Sheet
Executive Summary
Online retailer's net sales increase 41% to $84.3 mil. with a net loss of $6.3 mil. in the firm's third quarter, drugstore.com reports Oct. 26. Over-the-counter segment revenues rose 37% to $35.2 mil. due in part to a wider array of nutritional products. CEO Dawn Lepore says the firm has made "encouraging progress in a number of key areas despite a critical management transition and a seasonally challenging period." Lepore took over as CEO in September (1"The Tan Sheet" Sept. 27, 2004, In Brief)...
You may also be interested in...
Drugstore.com leadership
Online retailer appoints Dawn Lepore as CEO, effective Oct. 11. Lepore currently is VP-technology, operations and administration at Charles Schwab, a member of Schwab's executive committee and a trustee of SchwabFunds; she will relinquish all of her Schwab positions when she joins Drugstore.com. Drugstore.com board member Melinda Gates says Lepore "brings a great deal of respect and depth from the e-commerce industry as both a leader and an innovator," having designed Schwab's "entire technology platform" and played a "key role" in that firm's online brokerage business. Lepore replaces interim CEO and current CFO Robert Barton, who took over after Kal Raman stepped down in June (1"The Tan Sheet" June 14, 2004, In Brief)...
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.